Vir’s overhaul brings an end to most virology work — and a beginning with cancer

Last year’s layoffs were just the start for Vir Biotechnology.

The company is now shifting the direction of its clinical and corporate operations by prioritizing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Opinion | Is Industry Influence Driving LVAD Use by Cardiologists?

Dhruva is an assistant professor of medicine. Ross is a professor of medicine and public health. As physicians, our patients and their caregivers expect that

April 27, 2024

SPAC bust: ARCH, Deerfield and Section 32 cancel their $200M life sciences bet

A life sciences SPAC backed by industry investors Section 32, Deerfield Management and ARCH Venture Partners is closing shop well after the blank-check fad ended

July 25, 2023

Faron details clinical plans for MDS drug; Cara to seek ‘strategic’ options

Plus, news about CSL Vifor, Akebia and Pan Cancer T: Faron gets FDA go-ahead for streamlined registrational path: The company said the regulator “acknowledged the

July 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.